Zoritraz Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Zoritraz is particularly useful in patients who require oral antifungal therapy with good tissue penetration. The capsule formulation ensures optimal bioavailability when taken with food, enhancing absorption. Dosage should be individualized based on the severity and type of infection, with careful consideration of hepatic function due to potential hepatotoxicity. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Caution is advised in patients with cardiac conditions, as Itraconazole may cause negative inotropic effects. Drug interactions are significant, especially with agents metabolized by cytochrome P450 3A4; therefore, concomitant use with certain medications should be avoided or monitored closely. Regular liver function tests are recommended during prolonged therapy. Zoritraz Capsule should be used under strict medical supervision to ensure efficacy and safety.